Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintai Therapeutics Advances Anti-Obesity Agent KTX-0200 into IND-Enabling Studies Following Positive Preclinical Data Demonstrating Sustained Weight Loss and Improved Health Markers","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintai Therapeutics"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Endevica Bio\u2019s Lead Compound, TCMCB07, Published in \u201cACS Pharmacology & Translational Science\u201d Suggest a Platform Approach for Producing Drug-Like Peptides","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Endevica Bio"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Reports the U.S. FDA Accepted Its Investigational New Drug (IND) Application for TCMCB07, a Melanocortin\u20104 Antagonist Peptide","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Endevica Bio"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"9 Meters Biopharma"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"9 Meters Biopharma"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veru Announces Proposed Public Offering of Common Stock","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Veru"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Veru Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Veru"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Veru"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Skye Bioscience"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Peptide","graph2":"NeuroBo Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              NeuroBo Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

              Details:

              DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist, which is currently being evaluated for the treatment of obesity.

              Lead Product(s): DA-1726

              Therapeutic Area: Nutrition and Weight Loss Product Name: DA-1726

              Highest Development Status: IND Enabling Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 01, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Veru

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

              Details:

              VERU-024 (enobosarm) is a novel selective androgen receptor modulator which is beig evaluated in preclinical studies to prevent muscle loss while augmenting fat loss in combination with GLP-1 drugs for weight loss.

              Lead Product(s): Enobosarm,Undisclosed

              Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Veru

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Veru Announces Pricing of Public Offering of Common Stock

              Details:

              Veru intends to use the proceeds to fund its clinical stage drug development, including a Phase 2b trial to evaluate VERU-024 (enobosarm), an oral selective androgen receptor modulator, for the treatment to augment fat loss and to prevent muscle loss in sarcopenic obese.

              Lead Product(s): Enobosarm,Undisclosed

              Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Raymond James & Associates

              Deal Size: $33.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering December 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Veru

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Veru Announces Proposed Public Offering of Common Stock

              Details:

              Veru intends to use the proceeds to fund its clinical stage drug development, including a Phase 2b trial to evaluate VERU-024 (enobosarm), an oral selective androgen receptor modulator, for the treatment to augment fat loss and to prevent muscle loss in sarcopenic obese.

              Lead Product(s): Enobosarm,Undisclosed

              Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Raymond James & Associates

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Public Offering December 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Skye Bioscience

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

              Details:

              Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 receptor (CB1). Now it will undergo clinical development for the treatment of patients with obesity and chronic kidney disease.

              Lead Product(s): Nimacimab

              Therapeutic Area: Nutrition and Weight Loss Product Name: RYI-018

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              9 Meters Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

              Details:

              NM-136 is a novel humanized monoclonal antibody antagonist targeting glucose-dependent insulinotropic polypeptide (GIP). Pre-clinical data has demonstrated that anti-GIP monoclonal antibodies can effectively produce weight loss in obese mice without affecting food consumption.

              Lead Product(s): NM-136

              Therapeutic Area: Nutrition and Weight Loss Product Name: NM-136

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              9 Meters Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroentero...

              Details:

              NM-136, an anti-GIP humanized mAb, for targeted obesity disorders has demonstrated that the anti-GIP hu-mAb has a robust half-life, excellent humanness score, a high affinity for the GIP receptor.

              Lead Product(s): NM-136

              Therapeutic Area: Nutrition and Weight Loss Product Name: NM-136

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endevica Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endevica Reports the U.S. FDA Accepted Its Investigational New Drug (IND) Application for TCMCB07, a Melanocortin‐4 Antagonist Peptide

              Details:

              TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes.

              Lead Product(s): TCMCB07

              Therapeutic Area: Nutrition and Weight Loss Product Name: TCMCB07

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endevica Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Data on Endevica Bio’s Lead Compound, TCMCB07, Published in “ACS Pharmacology & Translational Science” Suggest a Platform Approach for Producing Drug-Like Peptide...

              Details:

              Endevica’s lead compound, TCMCB07, describes unique mechanisms and properties of drug, specifically in treatment of cachexia, and potential for producing a platform for drug-like peptides based on the evidence.

              Lead Product(s): TCMCB07

              Therapeutic Area: Nutrition and Weight Loss Product Name: TCMCB07

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kintai Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kintai Therapeutics Advances Anti-Obesity Agent KTX-0200 into IND-Enabling Studies Following Positive Preclinical Data Demonstrating Sustained Weight Loss and Improved Heal...

              Details:

              Treatment with KTX-0200 led to sustained weight loss of 14% in chronic diet-induced obesity rodent models known to be predictive of clinical efficacy across anti-obesity drug mechanisms.

              Lead Product(s): KTX-0200

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY